Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.46 |
| ▸ | SYK | P43405 | 8/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057874 | 0.91 | ZAP70 (0.46) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL13746496 | 0.88 | ZAP70 (0.45) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL1060202 | 0.88 | ZAP70 (0.45) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL1056395 | 0.88 | ZAP70 (0.45) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL13746494 | 0.88 | ZAP70 (0.45) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL1053641 | 0.87 | SYK (0.56) | JAK2SYKZAP70JAK1JAK3 | |
| SCHEMBL1057940 | 0.85 | ZAP70 (0.44) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL1057114 | 0.84 | SYK (0.45) | JAK2SYKBTKZAP70KCNH2 | |
| SCHEMBL1058717 | 0.84 | ZAP70 (0.46) | JAK2SYKZAP70JAK1JAK3 | |
| SCHEMBL1056757 | 0.84 | SYK (0.45) | JAK2SYKBTKZAP70JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | claimed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | claimed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | claimed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-8354526-B2 | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | IRM LLC (BM) | 2013-01-15 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2250169-A1 | PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099801-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003790-A1 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS | ZAP70, FLT3, LCK | JAK2 58/4885SYK 18/4885BTK 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.